SKF96022 (sodium hydrate)

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

S-Pantoprazole (sodium trihydrate), a variant of Pantoprazole, is pivotal in managing diseases associated with gastric acid secretion disorders, serving as a proton pump inhibitor [1].

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole-d6 is a deuterated compound of Pantoprazole. Pantoprazole has a CAS number of 102625-70-7. Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sulfide is a metabolite of the gastric H+/K+ ATPase pump inhibitor pantoprazole . Pantoprazole is metabolized by the cytochrome P450 (CYP) isomers CYP2C19 and CYP3A4 to form pantoprazole sulfide.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.